|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM316842516 |
| 003 |
DE-627 |
| 005 |
20250228065404.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108617
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1055.xml
|
| 035 |
|
|
|a (DE-627)NLM316842516
|
| 035 |
|
|
|a (NLM)33115645
|
| 035 |
|
|
|a (PII)S1521-6616(20)30777-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mastellos, Dimitrios C
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19"
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 22.01.2021
|
| 500 |
|
|
|a Date Revised 22.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a CommentOn: Clin Immunol. 2021 Jan;222:108618. doi: 10.1016/j.clim.2020.108618. - PMID 33127564
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Letter
|
| 650 |
|
4 |
|a Comment
|
| 650 |
|
7 |
|a Complement C3
|2 NLM
|
| 650 |
|
7 |
|a Pharmaceutical Preparations
|2 NLM
|
| 700 |
1 |
|
|a Lambris, John D
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 222(2021) vom: 20. Jan., Seite 108617
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:222
|g year:2021
|g day:20
|g month:01
|g pages:108617
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108617
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 222
|j 2021
|b 20
|c 01
|h 108617
|